

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Leo H. Wang		POSITION TITLE Assistant Professor, Department of Neurology	
eRA COMMONS USER NAME (credential, e.g., agency login)			
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
University of California, Berkley, CA	BA	05/97	Molecular Cell Biology
Washington University School of Medicine, Saint Louis, MO	MD, PhD	05/05	Medicine
Washington University School of Medicine Saint Louis, MO		06/06	Internship
Washington University School of Medicine Saint Louis, MO		06/09	Residency in Neurology
Washington University School of Medicine Saint Louis, MO		04/11	Fellowship in Neuromuscular medicine

A. Positions and Honors. List in chronological order previous positions, concluding with your present position. List any honors. Include present membership on any Federal Government public advisory committee.

- 8/93–5/97 Chancellor’s Scholarship, University of California, Berkeley, CA.
- 1/94 Edward Frank Kraft Scholarship Prize, University of California, Berkeley, CA.
- 1/94 Phi Beta Kappa, University of California, Berkeley, CA.
- 4/11 Leonard Berg Prize for research conducted during residency
- 12/09- present American Board of Psychiatry and Neurology
Board certified with added certification in neuromuscular medicine
- 7/11-present American Board of Electrodiagnostic Medicine
Board certified
- 8/11- present University of Washington School of Medicine, Seattle, WA
Department of Neurology
Division of neuromuscular medicine
Assistant Professor

B. Selected peer-reviewed publications (in chronological order). Do not include publications submitted or in preparation. For publicly available citations, URLs or PMC submission identification numbers may accompany the full reference; copies of publicly available publications are not accepted as appendix material.

- Wedemayer GJ, Patten PA, Wang LH, Schultz PG, Stevens RC (1997a) Structural insights into the evolution of an antibody combining site. Science 276:1665-1669.
- Wedemayer GJ, Wang LH, Patten PA, Schultz PG, Stevens RC (1997b) Crystal structures of the free and liganded form of an esterolytic catalytic antibody. J Mol Biol 268:390-400.

Program Director/Principal Investigator (Last, First, Middle): Chamberlain, Jeffrey S.

- Wang LH, Johnson EM, Jr. (2002) MLK inhibitors-treated sympathetic neurons use the phosphatidylinositol 3-kinase pathway to maintain trophism. In: Society for Neuroscience.
- Wang LH, Johnson EM, Jr. (2003) MLK inhibitor-treated sympathetic neurons activate the Trk receptor and the phosphatidylinositol 3-kinase pathway to maintain trophism and survival. In: Cold Spring Harbor Laboratory Meeting on Programmed Cell Death.
- Wang LH, Besirli CG, Johnson EM, Jr. (2004) Mixed-lineage kinases: a target for the prevention of neurodegeneration. *Annu Rev Pharmacol Toxicol* 44:451-474.
- Leitner ML, Wang LH, Osborne PA, Golden JP, Milbrandt J, Johnson EM, Jr. (2005) Expression and function of GDNF family ligands and receptors in the carotid body. *Exp Neurol* 191 Suppl 1:S68-79.
- Wang LH, Paden AJ, Johnson EM, Jr. (2005) Mixed-lineage kinase inhibitors require the activation of Trk receptors to maintain long-term neuronal trophism and survival. *J Pharmacol Exp Ther* 312:1007-1019.
- Gardner R, Wang LH, Ford A, Seyrouz S (2008) Spontaneous cerebral air embolism associated with remote lung surgery, a rare cause of stroke. *Neurocrit Care*. 8:434-6.
- Wang LH (2008) Seizure chapter in the Washington Manual of Outpatient Medicine
- Wang LH and Johnson EM, Jr. (2008) Letter to Editors of Neurology in response to article: Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease by The Parkinson Study Group PRECEPT Investigators
- Wang LH and Pestronk A (2011) Muscle pain chapter for Neurology in Clinical Practice, 6th Edition
- Wang LH, Bucelli RC, Patrick E, et al. (2013) Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease. *J Neurol* 260:498-506.
- Wang LH, Weiss MD. (2013) Anatomic, clinical, and electrodiagnostic features of radial neuropathies. *Physical Medicine & Rehabilitation Clinics of North America* 24(1), 33-47.
- Wang LH, Kraus, EE, Smith, C. Trigeminal nerve. In: Tasman W and Jaeger EA (Eds). *Duane's Ophthalmology*. Philadelphia. Lippincott Williams and Wilkins 2012.

C. Research Support. List selected ongoing or completed (during the last three years) research projects (federal and non-federal support). Begin with the projects that are most relevant to the research proposed in this application. Briefly indicate the overall goals of the projects and your role (e.g. PI, Co-Investigator, Consultant) in the research project. Do not list award amounts or percent effort in projects.

- 6/10 Principal Investigator
Planning grant from Barnes-Jewish Hospital Foundation and the Washington University Institute of Clinical and Translational Sciences entitled: "The role of NMDA receptor downregulation in anti-NMDA-receptor encephalitis"
- 7/09-6/10 Sub-PI for neuromuscular trials:
Clinical trial of ceftriaxone in subjects with amyotrophic lateral sclerosis
A double-blind, randomized, placebo-controlled trial of Etanercept for 12 months in subjects with inclusion body myositis
A 2-part, randomized, double-blind, safety and tolerability study evaluating KNS-760704 in patients with amyotrophic lateral sclerosis
KNS-760704-CL211: An open-label, safety and tolerability, study evaluating KNS-760704 in patients with amyotrophic lateral sclerosis
#LALS-001: A multicenter, double-blind, placebo-controlled, study to investigate the safety and efficacy of lithium in combination with Riluzole in Volunteers with amyotrophic lateral sclerosis (NEALS)
WALS: A multi-center controlled screening trial of safety and efficacy of lithium carbonate in subjects with amyotrophic lateral sclerosis

Program Director/Principal Investigator (Last, First, Middle): Chamberlain, Jeffrey S.

A randomized, double-blind, placebo controlled cross-over study of the effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy
A phase 2b efficacy and safety study of PTC124 in subjects with nonsense-mutation-mediated Duchenne and Becker muscular dystrophy
A Phase 2b extension study of PTC124 in subjects with nonsense-mutation-mediated Duchenne and Becker muscular dystrophy
A Phase 2a study of Ataluren (PTC 124) in nonambulatory patients with nonsense-mutation-mediated Duchenne and Becker muscular dystrophy
Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis Caused by SOD1 Gene Mutations
A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis

7/08-6/09

Sub-PI for the stroke trials:
EXTEND, Extending the Time for Thrombolysis in Emergency Neurological Deficits
IMS-3, Interventional Management of Stroke (IMS) III
APCAST, Activated Protein C in Acute Stroke Trial